Search research articles
Contact Us
Filters
Showing results (1-10 of 27) with videos related to
Page
of 3
Sort By:
Plos One
|
April 10, 2018
First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis
Mattias Neyt, Joan Vlayen, Stephan Devriese, et al.
Health Policy (Amsterdam, Netherlands)
|
July 10, 2018
A multi-criteria decision approach for ranking unmet needs in healthcare
Irina Cleemput, Stephan Devriese, Laurence Kohn, et al.
Pharmacoeconomics - Open
|
August 4, 2022
An EQ-5D-5L Value Set for Belgium
Nicolas Bouckaert, Irina Cleemput, Stephan Devriese, et al.
Pharmacoeconomics
|
January 11, 2025
Projections of Public Spending on Pharmaceuticals: A Review of Methods
Irina Odnoletkova, Patrice X Chalon, Stephan Devriese, et al.
Journal of Thrombosis and Thrombolysis
|
March 23, 2012
Economic evaluation of the use of point-of-care devices in patients with long term oral anticoagulation
Sophie Gerkens, Jeannine Gailly, Caroline Obyn, et al.
Health Policy (Amsterdam, Netherlands)
|
January 13, 2009
Cost-effectiveness analyses of drug eluting stents versus bare metal stents: a systematic review of the literature
Mattias Neyt, Hans Van Brabandt, Stephan Devriese, et al.
International Archives of Allergy and Immunology
|
June 30, 2021
Unraveling the Mystery of Polyvalent Immunoglobulins in Belgium: Do We Have an Indication?
Christophe de Meester, Jolyce Bourgeois, Stephan Devriese, et al.
BMC Pulmonary Medicine
|
September 17, 2010
Tiotropium's cost-effectiveness for the treatment of COPD: a cost-utility analysis under real-world conditions
Mattias Neyt, Stephan Devriese, Nancy Thiry, et al.
Consciousness and Cognition
|
September 1, 2004
Contingency awareness in a symptom learning paradigm: necessary but not sufficient?
Stephan Devriese, Winnie Winters, Ilse Van Diest, et al.
BMJ Open
|
May 8, 2012
A cost-utility analysis of transcatheter aortic valve implantation in Belgium: focusing on a well-defined and identifiable population
Mattias Neyt, Hans Van Brabandt, Stephan Devriese, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 27) with videos related to
Sort By:
Page
of 3
Plos One
|
April 10, 2018
First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis
Mattias Neyt, Joan Vlayen, Stephan Devriese, et al.
Health Policy (Amsterdam, Netherlands)
|
July 10, 2018
A multi-criteria decision approach for ranking unmet needs in healthcare
Irina Cleemput, Stephan Devriese, Laurence Kohn, et al.
Pharmacoeconomics - Open
|
August 4, 2022
An EQ-5D-5L Value Set for Belgium
Nicolas Bouckaert, Irina Cleemput, Stephan Devriese, et al.
Pharmacoeconomics
|
January 11, 2025
Projections of Public Spending on Pharmaceuticals: A Review of Methods
Irina Odnoletkova, Patrice X Chalon, Stephan Devriese, et al.
Journal of Thrombosis and Thrombolysis
|
March 23, 2012
Economic evaluation of the use of point-of-care devices in patients with long term oral anticoagulation
Sophie Gerkens, Jeannine Gailly, Caroline Obyn, et al.
Health Policy (Amsterdam, Netherlands)
|
January 13, 2009
Cost-effectiveness analyses of drug eluting stents versus bare metal stents: a systematic review of the literature
Mattias Neyt, Hans Van Brabandt, Stephan Devriese, et al.
International Archives of Allergy and Immunology
|
June 30, 2021
Unraveling the Mystery of Polyvalent Immunoglobulins in Belgium: Do We Have an Indication?
Christophe de Meester, Jolyce Bourgeois, Stephan Devriese, et al.
BMC Pulmonary Medicine
|
September 17, 2010
Tiotropium's cost-effectiveness for the treatment of COPD: a cost-utility analysis under real-world conditions
Mattias Neyt, Stephan Devriese, Nancy Thiry, et al.
Consciousness and Cognition
|
September 1, 2004
Contingency awareness in a symptom learning paradigm: necessary but not sufficient?
Stephan Devriese, Winnie Winters, Ilse Van Diest, et al.
BMJ Open
|
May 8, 2012
A cost-utility analysis of transcatheter aortic valve implantation in Belgium: focusing on a well-defined and identifiable population
Mattias Neyt, Hans Van Brabandt, Stephan Devriese, et al.
Page
of 3